Publications Cited in Medical Literature

1. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PDH, Sanders MM, Fine J. Prostate cancer and the Will Rogers phenomenon. (2005) Journal of the National Cancer Institute, 97 (17), pp. 1248-1253. Cited over 100 times to date.

2. Albertsen PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. (2005) Journal of the American Medical Association, 293(17), pp. 2095-2101. Cited over 260 times to date.

3. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. (2002) British Medical Journal, 325 (7367), pp. 740-743. Cited over 120 times to date.

4. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study. (2001) Journal of Clinical Oncology, 19 (17), pp. 3750-3757. Cited over 100 times to date.

5. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health outcomes after prostatectomy or radiotherapy for prostate cancer: Results from the prostate cancer outcomes study. (2000) Journal of the National Cancer Institute, 92 (19), pp. 1582-1592. Cited over 225 times to date.

6. Fowler FJ, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. (2000) Journal of the American Medical Association, 283 (24), pp. 3217-3222. Cited over 145 times to date.

7. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. (2000) Annals of Internal Medicine, 132(7), 566-577. Cited over 100 times to date.

8. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The prostate cancer outcomes study. (2000) Journal of the American Medical Association, 283 (3), pp. 354-360. Cited over 445 times to date.

9. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL. Expression of vascular endothelial growth factor receptors in human prostate cancer. (1999) Urology, 54 (3), pp. 567-572. Cited over 110 times to date.

10. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. (1998) Journal of the American Medical Association, 280(11), p. 975-980. Cited over 370 times to date.

11. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Logan Holtgrewe H, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. (1998) New England Journal of Medicine, 338 (9), pp. 557-563. Cited over 500 times to date.

12. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. (1998) Urology, 51 (1), pp. 161-167. Cited over 140 times to date.

13. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. (1997) Journal of Urology, 157(6), pp. 2329-2333. Cited over 155 times to date.

14. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. (1996) Journal of Urology, 156(1), pp. 127-132. Cited over 115 times to date.

15. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: A population-based study. (1996) Journal of the National Cancer Institute, 88 (3-4), pp. 166-172. Cited over 110 times to date.

16. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. (1995) Journal of the American Medical Association, 273 (7), pp. 548-552. Cited over 330 times to date.

17. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. (1995) Journal of the American Medical Association, 274 (8), pp. 626-631. Cited over 285 times to date.

18. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer (1993) Journal of the American Medical Association, 269 (20), pp. 2650-2658. Cited over 300 times to date.

Office Hours

8 a.m. to 4:30 p.m., Monday through Friday.

Office Locations

UConn Health Center
Dowling South Medical Building 263 Farmington Avenue
Farmington, CT 06030
Directions

UConn Medical Group
1115 West Street
Southington, CT 06489
Directions

Drs. Clement and Taylor Talk About a Team Approach to Treat Patients with Bladder Cancer

Interviews with Dr. Phillip Smith: Evaluation and Treatment of Common Voiding Problems